{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:51Z","timestamp":1793183211162,"version":"4.5.0"},"reference-count":230,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Staphylococcus aureus has been an exceptionally successful pathogen, which is still relevant in modern age-medicine due to its adaptability and tenacity. This bacterium may be a causative agent in a plethora of infections, owing to its abundance (in the environment and in the normal flora) and the variety of virulence factors that it possesses. Methicillin-resistant S. aureus (MRSA) strains\u2014first described in 1961\u2014are characterized by an altered penicillin-binding protein (PBP2a\/c) and resistance to all penicillins, cephalosporins, and carbapenems, which makes the \u03b2-lactam armamentarium clinically ineffective. The acquisition of additional resistance determinants further complicates their eradication; therefore, MRSA can be considered as the first representative of multidrug-resistant bacteria. Based on 230 references, the aim of this review is to recap the history, the emergence, and clinical features of various MRSA infections (hospital-, community-, and livestock-associated), and to summarize the current advances regarding MRSA screening, typing, and therapeutic options (including lipoglycopeptides, oxazolidinones, anti-MRSA cephalosporins, novel pleuromutilin-, tetracycline- and quinolone-derivatives, daptomycin, fusidic acid, in addition to drug candidates in the development phase), both for an audience of clinical microbiologists and infectious disease specialists.<\/jats:p>","DOI":"10.3390\/antibiotics8020052","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T03:15:22Z","timestamp":1556766922000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":244,"title":["The Continuing Threat of Methicillin-Resistant Staphylococcus aureus"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-0365","authenticated-orcid":false,"given":"M\u00e1ri\u00f3","family":"Gajd\u00e1cs","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"ref_1","unstructured":"Murray, P.R., Baron, E.J., Jorgensen, J.H., Landry, M.L., and Pfaller, M.A. (2007). Manual of Clinical Microbiology, American Society for Microbiology. [9th ed.]."},{"key":"ref_2","first-page":"425","article-title":"Taxonomy of Staphylococcus aureus","volume":"262","author":"Pulverer","year":"1986","journal-title":"Zentralbl. Bakteriol. Mikrobiol. Hyg. A."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1099\/00221287-5-5-1010","article-title":"Staphylococci and their Classification","volume":"5","author":"Shaw","year":"1951","journal-title":"J. Gen. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12223-010-0089-3","article-title":"Small colony variants of Staphylococcus aureus--review","volume":"55","author":"Melter","year":"2010","journal-title":"Folia Microbiol. (Praha)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/CMR.00109-13","article-title":"Coagulase-Negative Staphylococci","volume":"27","author":"Becker","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2702.1995.tb00004.x","article-title":"Staphylococcus aureus: A review of the literature","volume":"4","author":"Gould","year":"1995","journal-title":"J. Clin. Nurs."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/jac\/dkt072","article-title":"Antibiotic activity against small-colony variants of Staphylococcus aureus: Review of in vitro, animal and clinical data","volume":"68","author":"Garcia","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/CMR.00069-15","article-title":"Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections","volume":"29","author":"Kahl","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Proctor, R.A., Kriegeskorte, A., Kahl, B.C., Becker, K., L\u00f6ffler, B., and Peters, G. (2014). Staphylococcus aureus Small Colony Variants (SCVs): A road map for the metabolic pathways involved in persistent infections. Front. Cell. Infect. Microbiol., 4.","DOI":"10.3389\/fcimb.2014.00099"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Menetrey, A., Janin, A., Pullman, J., Overcash, J.S., Haouala, A., Leylavergne, F., Turbe, L., Wittke, F., and Nicolas-M\u00e9tral, V. (2019). Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01669-18"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.ijid.2010.09.012","article-title":"Clinical features and outcome of Staphylococcus aureus infection in elderly versus younger adult patients","volume":"15","author":"Kang","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.ajpath.2014.11.030","article-title":"Pathogenesis of Staphylococcus aureus Abscesses","volume":"185","author":"Kobayashi","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"643.e1","DOI":"10.1016\/j.cmi.2016.04.004","article-title":"Factors associated with severity in invasive community-acquired Staphylococcus aureus infections in children: A prospective European multicentre study","volume":"22","author":"Bellusci","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamapediatrics.2015.2380","article-title":"Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants","volume":"169","author":"Ericson","year":"2015","journal-title":"JAMA Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.4103\/0366-6999.219158","article-title":"Clinical and Molecular Epidemiology of Invasive Staphylococcus aureus Infections in Chinese Children: A Single-center Experience","volume":"130","author":"Wang","year":"2017","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Powers, M.E., and Wardenburg, J.B. (2014). Igniting the Fire: Staphylococcus aureus Virulence Factors in the Pathogenesis of Sepsis. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003871"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1128\/AEM.05316-11","article-title":"Expression of Virulence Factors by Staphylococcus aureus Grown in Serum","volume":"77","author":"Oogai","year":"2011","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11908-010-0119-y","article-title":"Staphylococcal toxic shock syndrome: Mechanisms and management","volume":"12","author":"Silversides","year":"2010","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bbrc.2007.01.072","article-title":"Staphylococcus aureus protein A induced inflammatory response in human corneal epithelial cells","volume":"354","author":"Kumar","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lacey, K.A., Geoghegan, J.A., and McLoughlin, R.M. (2016). The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine Antigens. Pathogens, 5.","DOI":"10.3390\/pathogens5010022"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gomes-Fernandes, M., Laabei, M., Pagan, N., Hidalgo, J., Molinos, S., Villar Hernandez, R., Dom\u00ednguez-Villanueva, D., Jenkins, A.T.A., Lacoma, A., and Prat, C. (2017). Accessory gene regulator (Agr) functionality in Staphylococcus aureus derived from lower respiratory tract infections. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175552"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.micpath.2018.05.046","article-title":"Developments in strategies for Quorum Sensing virulence factor inhibition to combat bacterial drug resistance","volume":"121","author":"Haque","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.50.4.1183-1194.2006","article-title":"Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance","volume":"50","author":"Seidl","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/00365548.2011.577801","article-title":"War and infection in the pre-antibiotic era: The Third Ottoman Army in 1915","volume":"43","author":"Erdem","year":"2011","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3201\/eid2305.161556","article-title":"The Discovery of Penicillin\u2014New Insights After More Than 75 Years of Clinical Use","volume":"23","author":"Gaynes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and Evolution of Antibiotic Resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/JCM.03068-13","article-title":"Performance of phenotypic tests for detection of penicillinase in Staphylococcus aureus isolates from Australia","volume":"52","author":"Papanicolas","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","first-page":"611","article-title":"Appropriate Prescribing of Oral Beta-Lactam Antibiotics","volume":"62","author":"Holten","year":"2000","journal-title":"AFP"},{"key":"ref_30","first-page":"135","article-title":"Penicillin\u2019s Discovery and Antibiotic Resistance: Lessons for the Future?","volume":"90","author":"Lobanovska","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001432-200304000-00007","article-title":"Staphylococcal resistance revisited: Community-acquired methicillin resistant Staphylococcus aureus\u2014An emerging problem for the management of skin and soft tissue infections","volume":"16","author":"Eady","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3181\/00379727-111-27850","article-title":"Inactivation of methicillin, oxacillin and ancillin by Staphylococcus aureus","volume":"111","author":"Sabath","year":"1962","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00404-010-1646-3","article-title":"Antibiotic chemotherapy during pregnancy and lactation period: Aspects for consideration","volume":"283","author":"Mylonas","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.idc.2016.02.004","article-title":"Multidrug Resistant Bacteria in the Community: Trends and Lessons Learned","volume":"30","author":"Paterson","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/0974-777X.157245","article-title":"Study of Antibiotic Resistance Pattern in Methicillin Resistant Staphylococcus Aureus with Special Reference to Newer Antibiotic","volume":"7","author":"Kaur","year":"2015","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_38","first-page":"249","article-title":"[The opinions of community pharmacists related to antibiotic use and resistance] (article in Hungarian)","volume":"88","author":"Paulik","year":"2018","journal-title":"Acta Pharm. Hung."},{"key":"ref_39","first-page":"26","article-title":"[The attitude of community pharmacists towards their widening roles in the prevention and treatment of infectious diseases in the southeast region of Hungary] (article in Hungarian)","volume":"63","author":"Paulik","year":"2019","journal-title":"Gy\u00f3gyszer\u00e9szet"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Santajit, S., and Indrawattana, N. (2016). Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed. Res. Int., 2016.","DOI":"10.1155\/2016\/2475067"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2017.08.026","article-title":"What is antimicrobial stewardship?","volume":"23","author":"Dyar","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ha, D.R., Haste, N.M., and Gluckstein, D.P. (2017). The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use. Am. J. Lifestyle Med.","DOI":"10.1177\/1559827617700824"},{"key":"ref_43","first-page":"714","article-title":"Prudent use of antibiotics","volume":"55","author":"Bergeron","year":"2014","journal-title":"Can. Vet. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1086\/321838","article-title":"Prudent Use of Antibiotics: Are Our Expectations Justified?","volume":"33","author":"Phillips","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","article-title":"The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)","volume":"19","author":"Lee","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_46","first-page":"31","article-title":"Extra deaths due to pandrug resistant bacteria: A survey of the literature","volume":"60","year":"2019","journal-title":"Eg\u00e9szs\u00e9gfejleszt\u00e9s"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of Mortality Associated with Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of Mortality in Staphylococcus aureus Bacteremia","volume":"25","author":"Jensen","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/IDR.S3545","article-title":"Current and novel antibiotics against resistant Gram-positive bacteria","volume":"1","author":"Perez","year":"2008","journal-title":"Infect. Drug Resist."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hassoun, A., Linden, P.K., and Friedman, B. (2017). Incidence, prevalence, and management of MRSA bacteremia across patient populations\u2014A review of recent developments in MRSA management and treatment. Crit. Care, 21.","DOI":"10.1186\/s13054-017-1801-3"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/jac\/dkf009","article-title":"Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials","volume":"49","author":"Graffunder","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/apm.1964.60.4.571","article-title":"Epidemic spread of Staphylococcus aureus PHAGE-TYPE 83A","volume":"60","author":"Rosendal","year":"1964","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1073\/pnas.122108599","article-title":"The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)","volume":"99","author":"Enright","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","first-page":"223","article-title":"Methicillin-Resistant Staphylococcus Aureus: A Pervasive Pathogen Highlights the Need for New Antimicrobial Development","volume":"83","author":"Morell","year":"2010","journal-title":"Yale J. Biol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(11)61566-3","article-title":"Five decades of MRSA: Controversy and uncertainty continues","volume":"378","author":"Cookson","year":"2011","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections","volume":"144","author":"King","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: The first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/428052","article-title":"Mechanisms of Resistance to Quinolones","volume":"41","author":"Jacoby","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Dukic, V.M., Lauderdale, D.S., Wilder, J., Daum, R.S., and David, M.Z. (2013). Epidemics of Community-Associated Methicillin-Resistant Staphylococcus aureus in the United States: A Meta-Analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052722"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"f1585","DOI":"10.1136\/bmj.f1585","article-title":"Outpatient parenteral antimicrobial therapy","volume":"346","author":"Chapman","year":"2013","journal-title":"BMJ"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2013\/205910","article-title":"Outpatient parenteral antimicrobial therapy","volume":"24","author":"Laupland","year":"2013","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.meegid.2013.08.011","article-title":"Staphylococcus aureus in veterinary medicine","volume":"21","author":"Peton","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/antibiotics4040521","article-title":"Livestock-Associated MRSA: The Impact on Humans","volume":"4","author":"Cuny","year":"2015","journal-title":"Antibiotics (Basel)"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijmm.2013.02.010","article-title":"Livestock associated MRSA (LA-MRSA) and its relevance for humans in Germany","volume":"303","author":"Cuny","year":"2013","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e003272","DOI":"10.1136\/bmjopen-2013-003272","article-title":"Risk factors for persistence of livestock-associated MRSA and environmental exposure in veal calf farmers and their family members: An observational longitudinal study","volume":"3","author":"Bos","year":"2013","journal-title":"BMJ Open"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sharma, M., Nunez-Garcia, J., Kearns, A.M., Doumith, M., Butaye, P.R., Argud\u00edn, M.A., Lahuerta-Marin, A., Pichon, B., AbuOun, M., and Rogers, J. (2016). Livestock-Associated Methicillin Resistant Staphylococcus aureus (LA-MRSA) Clonal Complex (CC) 398 Isolated from UK Animals belong to European Lineages. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01741"},{"key":"ref_69","unstructured":"Kevorkijan, B.K., Petrovi\u010d, \u017d., Kocuvan, A., and Rupnik, M. (2019). MRSA diversity and the emergence of LA-MRSA in a large teaching hospital in Slovenia. Acta Microbiol. Immunol. Hung., 1\u201312."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40588-016-0031-9","article-title":"Livestock-Associated MRSA and Its Current Evolution","volume":"3","author":"Butaye","year":"2016","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., Spengler, G., and Urb\u00e1n, E. (2017). Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik\u2019s Cube of Clinical Microbiology?. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040025"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","article-title":"Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O\u2019Toole 1935) Prevot 1938","volume":"40","author":"Lawson","year":"2016","journal-title":"Anaerobe"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1995-7645(14)60197-8","article-title":"Clostridium difficile infection: A review of the literature","volume":"7","author":"Khan","year":"2014","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1473-3099(18)30274-3","article-title":"Multidrug-resistant Neisseria gonorrhoeae: Implications for future treatment strategies","volume":"18","author":"MacFadden","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","article-title":"Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, prevention and drug treatment","volume":"63","author":"Rupp","year":"2003","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0035-1544208","article-title":"Carbapenemase-Producing Enterobacteriaceae","volume":"36","author":"Doi","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_77","unstructured":"(2019, March 27). CDC The biggest antibiotic-resistant threats in the U.S., Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest_threats.html."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Nasim, J., Witek, K., Kincses, A., Abdin, A.Y., \u017bes\u0142awska, E., Mar\u0107, M.A., Gajd\u00e1cs, M., Spengler, G., Nitek, W., and Latacz, G. (2019). Pronounced activity of aromatic selenocyanates against multidrug resistant ESKAPE bacteria. New J. Chem., 15.","DOI":"10.1039\/C9NJ00563C"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for Gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M. (2019). The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules, 24.","DOI":"10.3390\/molecules24050892"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2017.01.003","article-title":"What is an \u201cideal\u201d antibiotic? Discovery challenges and path forward","volume":"133","author":"Singh","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2174\/1568026618666180816162846","article-title":"Novel Classes of Antibacterial Drugs in Clinical Development, a Hope in a Post-antibiotic Era","volume":"18","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_84","unstructured":"(2019, March 27). Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug Resistant Bacterial Infections, Including Tuberculosis. Available online: http:\/\/www.who.int\/medicines\/areas\/rational_use\/prioritization-of-pathogens\/en\/."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijantimicag.2011.09.030","article-title":"Meticillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods","volume":"39","author":"Stefani","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3201\/eid1605.091851","article-title":"Methicillin-Resistant Staphylococcus aureus Carriage and Risk Factors for Skin Infections, Southwestern Alaska, USA","volume":"16","author":"Stevens","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.meegid.2013.03.020","article-title":"Staphylococcus aureus: Determinants of human carriage","volume":"21","author":"Sollid","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1592\/phco.29.3.263","article-title":"Agents for the decolonization of methicillin-resistant Staphylococcus aureus","volume":"29","author":"McConeghy","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2215\/CJN.06270710","article-title":"Nasal Carriage of Methicillin-resistant Staphylococcus aureus Is Associated with Higher All-Cause Mortality in Hemodialysis Patients","volume":"6","author":"Lai","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Dulon, M., Peters, C., Schablon, A., and Nienhaus, A. (2014). MRSA carriage among healthcare workers in non-outbreak settings in Europe and the United States: A systematic review. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-363"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/JCM.41.7.3163-3166.2003","article-title":"Comparison of Culture Screening Methods for Detection of Nasal Carriage of Methicillin-Resistant Staphylococcus aureus: A Prospective Study Comparing 32 Methods","volume":"41","author":"Safdar","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mimet.2017.11.021","article-title":"Combination of MALDI-TOF MS and PBP2\u2019 latex agglutination assay for rapid MRSA detection","volume":"144","year":"2018","journal-title":"J. Microbiol. Methods"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/JCM.00601-09","article-title":"Comparison of MRSASelect Agar, CHROMagar Methicillin-Resistant Staphylococcus aureus (MRSA) Medium, and Xpert MRSA PCR for Detection of MRSA in Nares: Diagnostic Accuracy for Surveillance Samples with Various Bacterial Densities","volume":"47","author":"Wolk","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","article-title":"EUCAST expert rules in antimicrobial susceptibility testing","volume":"19","author":"Leclercq","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_95","unstructured":"(2017, September 10). Clinical and Laboratory Standards Institute (CLSI). Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JCM.01506-08","article-title":"Comparison of Cefoxitin and Oxacillin Disk Diffusion Methods for Detection of mecA-Mediated Resistance in Staphylococcus aureus in a Large-Scale Study","volume":"47","author":"Broekema","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/JCM.01884-08","article-title":"Rapid Detection of Staphylococcus aureus and Methicillin-Resistant S. aureus (MRSA) in Wound Specimens and Blood Cultures: Multicenter Preclinical Evaluation of the Cepheid Xpert MRSA\/SA Skin and Soft Tissue and Blood Culture Assays","volume":"47","author":"Wolk","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Benagli, C., Rossi, V., Dolina, M., Tonolla, M., and Petrini, O. (2011). Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for the Identification of Clinically Relevant Bacteria. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016424"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1128\/AAC.00187-11","article-title":"Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus","volume":"55","author":"Shore","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/CMR.3.1.46","article-title":"The life and times of the Enterococcus","volume":"3","author":"Murray","year":"1990","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0923-2508(00)00170-4","article-title":"Transformation in Streptococcus pneumoniae: Mosaic genes and the regulation of competence","volume":"151","author":"Hakenbeck","year":"2000","journal-title":"Res. Microbiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.meegid.2008.07.007","article-title":"The evolution of Staphylococcus aureus","volume":"8","author":"Deurenberg","year":"2008","journal-title":"Infect. Genet. Evol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-62703-664-1_8","article-title":"Staphylococcal Cassette Chromosome mec (SCCmec) analysis of MRSA","volume":"1085","author":"Ito","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/AAC.02302-16","article-title":"Evolutionary Origin of the Staphylococcal Cassette Chromosome mec (SCCmec)","volume":"61","author":"Rolo","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.meegid.2018.03.013","article-title":"Novel SCCmec type XIII (9A) identified in an ST152 methicillin-resistant Staphylococcus aureus","volume":"61","author":"Baig","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Otto, M. (2017). Next-generation sequencing to monitor the spread of antimicrobial resistance. Genome. Med., 9.","DOI":"10.1186\/s13073-017-0461-x"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(00)04403-2","article-title":"Whole genome sequencing of meticillin-resistant Staphylococcus aureus","volume":"357","author":"Kuroda","year":"2001","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/j.1462-5822.2012.01832.x","article-title":"MRSA virulence and spread","volume":"14","author":"Otto","year":"2012","journal-title":"Cell. Microbiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3201\/eid1211.060726","article-title":"Panton-Valentine Leukocidin\u2013producing Staphylococcus aureus","volume":"12","author":"Adler","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Bhatta, D.R., Cavaco, L.M., Nath, G., Kumar, K., Gaur, A., Gokhale, S., and Bhatta, D.R. (2016). Association of Panton Valentine Leukocidin (PVL) genes with methicillin resistant Staphylococcus aureus (MRSA) in Western Nepal: A matter of concern for community infections (a hospital based prospective study). BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1531-1"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/13102818.2014.976457","article-title":"Panton-Valentine leukocidin in community and hospital-acquired Staphylococcus aureus strains","volume":"28","author":"Dal","year":"2014","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1128\/AAC.02731-13","article-title":"The mecA Homolog mecC Confers Resistance against \u03b2-Lactams in Staphylococcus aureus Irrespective of the Genetic Strain Background","volume":"58","author":"Ballhausen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tim.2013.11.003","article-title":"The emergence of mecC methicillin-resistant Staphylococcus aureus","volume":"22","author":"Paterson","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/JCM.01815-14","article-title":"Methicillin-Resistant Staphylococcus aureus Harboring mecC in Livestock in Spain","volume":"52","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-59745-468-1_6","article-title":"Multilocus sequence typing (MLST) of Staphylococcus aureus","volume":"391","author":"Saunders","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-62703-664-1_6","article-title":"Pulsed-field gel electrophoresis typing of Staphylococcus aureus isolates","volume":"1085","author":"He","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Bosch, T., de Neeling, A.J., Schouls, L.M., Van der Zwaluw, K.W., Kluytmans, J.A., Grundmann, H., and Huijsdens, X.W. (2010). PFGE diversity within the methicillin-resistant Staphylococcus aureus clonal lineage ST398. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-40"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3343\/alm.2017.37.6.553","article-title":"Performance of Matrix-Assisted Laser Desorption Ionization Time-of-Fight Mass Spectrometry for Rapid Discrimination of Methicillin-Resistant Staphylococcus aureus (MRSA): First Report of a Relation Between Protein Peaks and MRSA spa Type","volume":"37","author":"Kwon","year":"2017","journal-title":"Ann. Lab. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/JCM.42.2.792-799.2004","article-title":"spa Typing Method for Discriminating among Staphylococcus aureus Isolates: Implications for Use of a Single Marker to Detect Genetic Micro- and Macrovariation","volume":"42","author":"Koreen","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-60327-999-4_15","article-title":"spa typing for epidemiological surveillance of Staphylococcus aureus","volume":"551","author":"Hallin","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1574-6976.2011.00298.x","article-title":"Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology","volume":"36","author":"Croxatto","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Manukumar, H.M., and Umesha, S. (2017). MALDI-TOF-MS based identification and molecular characterization of food associated methicillin-resistant Staphylococcus aureus. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-11597-z"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1128\/JCM.00029-17","article-title":"Comparison of Whole-Genome Sequencing Methods for Analysis of Three Methicillin-Resistant Staphylococcus aureus Outbreaks","volume":"55","author":"Cunningham","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_124","first-page":"45","article-title":"Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections","volume":"2","author":"Bhambri","year":"2009","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1128\/AAC.00706-11","article-title":"Dose of Trimethoprim-Sulfamethoxazole To Treat Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus","volume":"55","author":"Cadena","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.29.5.733","article-title":"Plasmid-encoded trimethoprim resistance in staphylococci","volume":"29","author":"Archer","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1099\/00222615-26-1-67","article-title":"Trimethoprim resistance determinants encoding a dihydrofolate reductase in clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci","volume":"26","author":"Tennent","year":"1988","journal-title":"J. Med. Microbiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365549109023379","article-title":"Occurrence of doxycycline resistant bacteria in the oral cavity after local administration of doxycycline in patients with periodontal disease","volume":"23","author":"Larsen","year":"1991","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antibiotics2010028","article-title":"Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus","volume":"2","author":"Handzlik","year":"2013","journal-title":"Antibiotics (Basel)"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cmdc.201700286","article-title":"Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues","volume":"12","author":"Felicetti","year":"2017","journal-title":"ChemMedChem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1128\/AAC.00289-11","article-title":"Implication of the NorB Efflux Pump in the Adaptation of Staphylococcus aureus to Growth at Acid pH and in Resistance to Moxifloxacin","volume":"55","author":"Bolduc","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Spengler, G., Kincses, A., Gajdacs, M., and Amaral, L. (2017). New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules, 22.","DOI":"10.3390\/molecules22030468"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond Vancomycin: The Tail of the Lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_134","unstructured":"Brunton, L., Chabner, B.A., and Knollman, B. (2011). Goodman & Gillman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill. [12th ed.]."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1128\/AAC.00115-11","article-title":"Prediction of Failure in Vancomycin-Treated Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Clinically Useful Risk Stratification Tool","volume":"55","author":"Moore","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: A review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J. Clin. Invest."},{"key":"ref_138","first-page":"269","article-title":"Vancomycin Resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to Know","volume":"32","author":"Weinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.41.1.66","article-title":"Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues","volume":"41","author":"Allen","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","article-title":"Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods","volume":"47","author":"Liu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14787210.7.1.1","article-title":"hVISA\/VISA: Diagnostic and therapeutic problems","volume":"7","year":"2009","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","article-title":"In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014","volume":"46","author":"Biedenbach","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00002018-200831090-00004","article-title":"Benefit-risk assessment of linezolid for serious gram-positive bacterial infections","volume":"31","author":"Falagas","year":"2008","journal-title":"Drug Saf."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/AAC.05702-11","article-title":"Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome","volume":"56","author":"Long","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/ph3071988","article-title":"Linezolid Resistance in Staphylococci","volume":"3","author":"Stefani","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1128\/AAC.02955-14","article-title":"Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16","volume":"58","author":"Mensa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dkm437","article-title":"Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia","volume":"61","author":"Lalani","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12948","article-title":"Mechanisms of drug resistance: Daptomycin resistance","volume":"1354","author":"Tran","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1345\/aph.1L016","article-title":"Ceftobiprole: An extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin","volume":"42","author":"Anderson","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_155","first-page":"631","article-title":"Ceftobiprole, a Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)","volume":"33","author":"Kisgen","year":"2008","journal-title":"P.T."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Duplessis, C., and Crum-Cianflone, N.F. (2011). Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Clin. Med. Rev. Ther., 3.","DOI":"10.4137\/CMRT.S1637"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2012.12.013","article-title":"Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)","volume":"41","author":"Farrell","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/jac\/dkv179","article-title":"Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline","volume":"70","author":"Livermore","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti\u2013methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.medmal.2010.12.013","article-title":"In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008","volume":"41","author":"Bourdon","year":"2011","journal-title":"Med. Mal. Infect."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Urb\u00e1n, E., and Stone, G.G. (2019). Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft tissue infections. Clin. Microbiol. Infect.","DOI":"10.1016\/j.cmi.2019.03.023"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.05004-14","article-title":"Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant Staphylococcus aureus","volume":"59","author":"Chan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Tong, S.Y.C., Nelson, J., Paterson, D.L., Fowler, V.G., Howden, B.P., Cheng, A.C., Chatfield, M., Lipman, J., Van Hal, S., and O\u2019Sullivan, M. (2016). CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: Study protocol for a randomised controlled trial. Trials, 17.","DOI":"10.1186\/s13063-016-1295-3"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: What is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Florescu, I., Beuran, M., Dimov, R., Razbadauskas, A., Bochan, M., Fichev, G., Dukart, G., Babinchak, T., Cooper, C.A., and Ellis-Grosse, E.J. (2008). Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A Phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother., 62.","DOI":"10.1093\/jac\/dkn250"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.00985-09","article-title":"Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model","volume":"53","author":"Koomanachai","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14787210.2014.894882","article-title":"The role of tigecycline in the treatment of infections in light of the new black box warning","volume":"12","author":"Dixit","year":"2014","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Solomkin, J.S., Gardovskis, J., Lawrence, K., Montravers, P., Sway, A., Evans, D., and Tsai, L. (2018). IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciy1029"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Dougherty, J.A., Sucher, A.J., Chahine, E.B., and Shihadeh, K.C. (2018). Omadacycline: A New Tetracycline Antibiotic. Ann. Pharmacother.","DOI":"10.1177\/1060028018818094"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2014.04.034","article-title":"Novel organic salts based on fluoroquinolone drugs: Synthesis, bioavailability and toxicological profiles","volume":"469","author":"Florindo","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: Design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"McCurdy, S., Lawrence, L., Quintas, M., Woosley, L., Flamm, R., Tseng, C., and Cammarata, S. (2017). In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00772-17"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1128\/AAC.01407-05","article-title":"In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone","volume":"50","author":"Park","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01197-09","article-title":"Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates","volume":"54","author":"Lauderdale","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Park, H.S., Oh, S.H., Kim, H.S., Choi, D.R., and Kwak, J.H. (2016). Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae. Molecules, 21.","DOI":"10.3390\/molecules21111562"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","article-title":"Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study","volume":"5","author":"Daneman","year":"2015","journal-title":"BMJ Open"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/jac\/dkm409","article-title":"In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action","volume":"60","author":"Laue","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1345\/aph.1L167","article-title":"Iclaprim, A novel diaminopyrimidine for the treatment of resistant gram-positive infections","volume":"43","author":"Sincak","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_182","first-page":"761","article-title":"Mupirocin: A topical antibiotic with a unique structure and mechanism of action","volume":"6","author":"Parenti","year":"1987","journal-title":"Clin. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/jac\/dkv169","article-title":"Mupirocin resistance: Clinical implications and potential alternatives for the eradication of MRSA","volume":"70","author":"Poovelikunnel","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1128\/AAC.00523-10","article-title":"Fusidic Acid Resistance Determinants in Staphylococcus aureus Clinical Isolates","volume":"54","author":"Chen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/adc.2003.019695","article-title":"Fusidic acid resistance in Staphylococcus aureus","volume":"89","author":"Dobie","year":"2004","journal-title":"Arch. Dis. Child."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Paukner, S., and Riedl, R. (2017). Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance. Cold Spring Harb. Perspect. Med., 7.","DOI":"10.1101\/cshperspect.a027110"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/17460913.2.6.591","article-title":"Retapamulin: A semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children","volume":"2","author":"Jacobs","year":"2007","journal-title":"Future Microbiol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/AAC.00358-13","article-title":"Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-015-0096-x","article-title":"Efficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practice","volume":"4","author":"Sai","year":"2015","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Kumar, P., Kizhakkedathu, J.N., and Straus, S.K. (2018). Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules, 8.","DOI":"10.3390\/biom8010004"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2174\/1568026616666160713130452","article-title":"Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications","volume":"17","author":"Scott","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1128\/AEM.02388-08","article-title":"Staphylococcus aureus virulence expression is impaired by Lactococcus lactis in mixed cultures","volume":"75","author":"Even","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrmicro1818","article-title":"The biology and future prospects of antivirulence therapies","volume":"6","author":"Cegelski","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1073\/pnas.1720520115","article-title":"Suppression of Staphylococcus aureus virulence by a small-molecule compound","volume":"115","author":"Gao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Amaral, L., Martins, A., Spengler, G., and Molnar, J. (2014). Efflux pumps of Gram-negative bacteria: What they do, how they do it, with what and how to deal with them. Front Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00168"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2174\/138161211795703726","article-title":"Microbial Efflux Pump Inhibition: Tactics and Strategies","volume":"17","author":"Tegos","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1139\/cjm-2014-0063","article-title":"Something old, something new: Revisiting natural products in antibiotic drug discovery","volume":"60","author":"Wright","year":"2014","journal-title":"Can. J. Microbiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bmcl.2013.12.059","article-title":"New natural products as new leads for antibacterial drug discovery","volume":"24","author":"Brown","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3855\/jidc.3573","article-title":"Bacteriophage therapy: A potential solution for the antibiotic resistance crisis","volume":"8","author":"Golkar","year":"2014","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Love, M.J., Bhandari, D., Dobson, R.C.J., and Billington, C. (2018). Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care. Antibiotics (Basel), 7.","DOI":"10.3390\/antibiotics7010017"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaci.2018.08.038","article-title":"Next-generation anti-Staphylococcus aureus vaccines: A potential new therapeutic option for atopic dermatitis?","volume":"143","author":"Clowry","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2165\/00003495-200666140-00002","article-title":"Antistaphylococcal vaccines and immunoglobulins: Current status and future prospects","volume":"66","author":"Deresinski","year":"2006","journal-title":"Drugs"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.biochi.2010.02.023","article-title":"Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity","volume":"92","author":"Takahashi","year":"2010","journal-title":"Biochimie"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"13896","DOI":"10.1074\/jbc.M311418200","article-title":"Helix stability confers salt resistance upon helical antimicrobial peptides","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00726-014-1778-z","article-title":"Poly-lysine peptidomimetics having potent antimicrobial activity without hemolytic activity","volume":"46","author":"Ahn","year":"2014","journal-title":"Amino Acids"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"135102","DOI":"10.1088\/1361-6528\/aa5f63","article-title":"Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157:H7 and methicillin resistant Staphylococcus aureus (MRSA)","volume":"28","author":"Cruz","year":"2017","journal-title":"Nanotechnology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nri1180","article-title":"Defensins: Antimicrobial peptides of innate immunity","volume":"3","author":"Ganz","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijmm.2013.08.007","article-title":"Defensin-based anti-infective strategies","volume":"304","author":"Wilmes","year":"2014","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fmb.12.97","article-title":"Bacteriophage endolysins as novel antimicrobials","volume":"7","author":"Schmelcher","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: An alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J. Gastrointest Pharmacol. Ther."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1432-1033.1996.0689r.x","article-title":"The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA","volume":"242","author":"Bergler","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.str.2012.03.013","article-title":"Staphylococcus aureus FabI: Inhibition, Substrate Recognition and Potential Implications for In Vivo Essentiality","volume":"20","author":"Schiebel","year":"2012","journal-title":"Structure"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Hibbitts, A., and O\u2019Leary, C. (2018). Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus. Materials (Basel), 11.","DOI":"10.3390\/ma11020321"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/polym3010340","article-title":"New Strategies in the Development of Antimicrobial Coatings: The Example of Increasing Usage of Silver and Silver Nanoparticles","volume":"3","author":"Knetsch","year":"2011","journal-title":"Polymers"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"495101","DOI":"10.1088\/0957-4484\/23\/49\/495101","article-title":"Antibacterial effect of zinc oxide nanoparticles combined with ultrasound","volume":"23","author":"Seil","year":"2012","journal-title":"Nanotechnology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.2147\/IJN.S29020","article-title":"Size-dependent antimicrobial properties of CuO nanoparticles against Gram-positive and -negative bacterial strains","volume":"7","author":"Azam","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1073\/pnas.1107254109","article-title":"Nanoalumina promotes the horizontal transfer of multiresistance genes mediated by plasmids across genera","volume":"109","author":"Qiu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0968-0896(01)00044-X","article-title":"Dicationic dithiocarbamate carbapenems with anti-MRSA activity","volume":"9","author":"Imamura","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/jac\/dkp187","article-title":"Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms","volume":"64","author":"Livermore","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7164\/antibiotics.55.722","article-title":"New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1beta-methyl-2-(thiazol-2-ylthio)carbapenems","volume":"55","author":"Sunagawa","year":"2002","journal-title":"J. Antibiot."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciy659","article-title":"In Vitro Activities of Ceftaroline\/Avibactam, Ceftazidime\/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China","volume":"67","author":"Zhou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and Class C \u03b2-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/bit.25851","article-title":"Current and future prospects for CRISPR-based tools in bacteria","volume":"113","author":"Luo","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jac\/dki416","article-title":"Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo","volume":"57","author":"Yanagihara","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/cc13948","article-title":"The future of antibiotics","volume":"18","author":"Spellberg","year":"2014","journal-title":"Crit. Care"},{"key":"ref_227","first-page":"67","article-title":"Prediction of ADME properties for selenocompounds with anticancer and efflux pump inhibitory activity using preliminary computational methods (article in Hungarian)","volume":"88","author":"Handzlik","year":"2018","journal-title":"Acta Pharm. Hung."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2217\/pgs.14.147","article-title":"Pharmacogenomics of antimicrobial agents","volume":"15","author":"Aung","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-7799(01)01846-7","article-title":"Protein therapeutics: Promises and challenges for the 21st century","volume":"20","author":"Weng","year":"2002","journal-title":"Trends Biotechnol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmi.2017.09.017","article-title":"Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage","volume":"24","author":"Burdet","year":"2018","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:48:45Z","timestamp":1760186925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":230,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["antibiotics8020052"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics8020052","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]}}}